ICU Medical (NASDAQ:ICUI) Updates FY 2025 Earnings Guidance

ICU Medical (NASDAQ:ICUI) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 6.550-7.250 for the period, compared to the consensus EPS estimate of 7.130. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th. KeyCorp increased their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price on the stock in a research report on Wednesday, December 11th. Finally, StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $199.67.

ICU Medical Price Performance

ICUI stock opened at $149.75 on Friday. ICU Medical has a 1 year low of $93.36 and a 1 year high of $196.26. The firm has a market capitalization of $3.67 billion, a PE ratio of -32.77 and a beta of 0.63. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The business has a 50 day simple moving average of $160.63 and a 200-day simple moving average of $166.09.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 1,373 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,262,119.64. This represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 6.70% of the stock is currently owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.